कंपनी का अवलोकन
Cabaletta Bio, Inc. is a clinical-stage biotechnology firm dedicated to the discovery and development of engineered T cell therapies specifically designed for patients suffering from autoimmune diseases. The company operates within the healthcare sector and functions in the biotechnology industry, where it focuses on advancing novel cellular immunotherapies rather than traditional small-molecule drugs. Its current scale is defined by a market capitalization of $352.89M and a workforce comprising 154 employees, while reported revenue and earnings data for the trailing twelve months are not available in the provided financial records. The valuation metric of $352.89M market cap indicates that the market is pricing the company based on its future pipeline potential and asset value rather than current cash flows or sales, which is typical for clinical-stage entities.
वित्तीय स्वास्थ्य
The company reports a net income of $-167,856,000 and an EBITDA of $-170,595,008 for the trailing twelve months, reflecting the significant capital expenditure required to advance clinical trials. The gap between revenue, which is not disclosed, and net income reveals a cost structure heavily weighted toward research and development expenses and operational burn rather than commercial profit generation. Free cash flow stands at $-81,283,128, indicating that the company is currently consuming cash to fund its operations and drug development efforts rather than generating liquidity from core business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not yet achieved commercial scale or that non-operating expenses have completely offset any revenue-generated margins. In terms of solvency, the company holds $133.60M in cash against $27.10M in debt, resulting in a debt-to-equity ratio of 24.18, suggesting a balance sheet that is leveraged but currently supported by substantial cash reserves. The current ratio of 2.77 indicates a strong position in short-term liquidity, meaning the firm possesses 2.77 times the assets needed to cover its current liabilities. Return on Equity is reported at -127.0% and Return on Assets at -61.5%, metrics that reveal that management is currently destroying shareholder value through operational losses rather than generating returns, a common characteristic of pre-revenue biotech firms.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E stands at -2.26, implying that the market expects earnings to remain negative in the near future based on current projections. The price-to-book ratio is 2.84, indicating that the market is valuing the company at a significant premium of 2.84 times its net asset book value, likely due to the intangible value of its clinical pipeline and intellectual property. The price-to-sales ratio is N/A because revenue figures are not available, and the EV/EBITDA multiple is -1.44, which suggests a valuation framework where the enterprise value is being weighed against substantial negative earnings. The stock has traded between a 52-week high of $3.78 and a 52-week low of $1.01, placing the current share price at a specific point within this volatility range relative to the broader market history. The beta value of 3.29 indicates that the stock price is highly volatile and tends to move with significantly greater magnitude than the broader market index, reflecting the high risk profile associated with clinical-stage biotechnology investments.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between top-line sales and bottom-line profitability as traditional metrics are unavailable for this clinical-stage entity. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which means the firm retains all available cash to reinvest into its drug development programs and operational expansion rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology companies at this stage, where capital is prioritized for clinical trials and regulatory filings over shareholder payouts. Consequently, the overall growth and income profile is characterized by a complete reliance on internal cash generation and external financing to sustain operations, with no current mechanism for generating income for investors through dividends or sales growth.